Explore the words cloud of the IPOG project. It provides you a very rough idea of what is the project "IPOG" about.
The following table provides information about the project.
METABOLOMIC DIAGNOSTICS LIMITED
|Coordinator Country||Ireland [IE]|
|Total cost||2˙705˙750 €|
|EC max contribution||1˙894˙025 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-11-01 to 2020-10-31|
Take a look of project's partnership.
|1||METABOLOMIC DIAGNOSTICS LIMITED||IE (Cork)||coordinator||1˙894˙025.00|
Preeclampsia is responsible for the deaths of more than 70,000 mothers and half a million babies each year. Identifying those mothers at risk of preeclampsia is difficult. The current gold standard in prenatal care does not detect the disease early enough to change the course of the disease.
MDx has developed PrePsia™, a simple blood test which identifies an expectant mother’s risk of preterm preeclampsia, up to 5 months before most women will display clinical symptoms. Clinicians can now use this simple tool, to personalise pregnancy care, including the initiation of treatments in early pregnancy that can dramatically reduce the incidence of preterm preeclampsia by 62%3. In the EU, with about 5.1 million births per annum (2015 data) , treating the women identified at high risk for preterm preeclampsia by PrePsia™ has the potential to prevent over 37,000 cases of preterm preeclampsia and its associated severe outcomes, every year.
The only other test in the market that screens for preterm preeclampsia, is complex and requires for specialist ultrasound scans to be taken, which are expensive, subjective and require for dedicated ultrasound equipment and operators.
MDx has a portfolio of IP assets, as developed by the company over the last 5 years, that will protect PrePsia™ and also have significant commercial potential beyond just the realm of preeclampsia.
MDx has team of successful serial entrepreneurs coupled with globally renewed technical expertise to deliver PrePsia™ to the market and build a long term self-sustaining European company.
By year 4 MDx will have annualised revenues of €69 million and employment for 50 people while fulfilling its ambition to become a world leader in innovative pregnancy diagnostics.
|year||authors and title||journal||last update|
Metabolomic Diagnostics Ltd
PrePsia: A screening test for preterm pre-eclampsia in first time pregnant women without overt risk factors (white paper).
published pages: , ISSN: , DOI:
Matias C Vieira, Gregoire Thomas, Lucilla Poston, Robin Tuytten, Dharmintra Pasupathy
Metabolite biomarkers for early prediction of pre-eclampsia in women with obesity
published pages: , ISSN: , DOI:
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPOG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IPOG" are provided by the European Opendata Portal: CORDIS opendata.